Literature DB >> 17213358

Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.

Chor-Sang Chim1, Raymond Liang, Man-Hin Leung, Yok-Lam Kwong.   

Abstract

Malignant transformation is a multistep process that may involve dysregulation of oncogenes and tumour suppressor genes, and monoclonal gammopathy of undetermined significance (MGUS) is believed to be a precursor of multiple myeloma. To investigate whether aberrant promoter methylation might be involved in the evolution of MGUS to multiple myeloma, we examined the p16, protein tyrosine phosphatase, non-receptor type 6 (SHP1), death-associated protein (DAP) kinase, E-cadherin and oestrogen receptor genes, most being tumour suppressor genes, by methylation-specific polymerase chain reaction. In 32 cases of multiple myeloma and 19 cases of MGUS, significantly more frequent methylation of p16 (p = 0.001), SHP1 (p< or =0.001) and E-cadherin (p< or =0.001) genes was found in multiple myeloma than in MGUS. Methylation of DAP kinase and oestrogen receptor genes was comparable in multiple myeloma and MGUS. In conclusion, methylation of p16, SHP1 and E-cadherin genes might be involved in the progression of MGUS to multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17213358      PMCID: PMC1860599          DOI: 10.1136/jcp.2006.036715

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

Review 1.  Gene silencing in cancer in association with promoter hypermethylation.

Authors:  James G Herman; Stephen B Baylin
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

2.  Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia.

Authors:  T Uchida; T Kinoshita; T Ohno; H Ohashi; H Nagai; H Saito
Journal:  Leukemia       Date:  2001-01       Impact factor: 11.528

3.  p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance.

Authors:  G Guillerm; E Gyan; D Wolowiec; T Facon; H Avet-Loiseau; K Kuliczkowski; F Bauters; P Fenaux; B Quesnel
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

Review 4.  Multiple myeloma: evolving genetic events and host interactions.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

5.  p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies.

Authors:  M V Mateos; R Garcia-Sanz; R López-Pérez; A Balanzategui; M I González; J Fernández-Calvo; M J Moro; J Hernández; M D Caballero; M González; J F San Miguel
Journal:  Hematol J       Date:  2001

6.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

7.  SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway.

Authors:  Chor-Sang Chim; Tsz-Kin Fung; Wai-Chung Cheung; Raymond Liang; Yok-Lam Kwong
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

8.  DNA methylation changes in multiple myeloma.

Authors:  O Galm; S Wilop; J Reichelt; E Jost; G Gehbauer; J G Herman; R Osieka
Journal:  Leukemia       Date:  2004-10       Impact factor: 11.528

9.  DNA methylation profiles of lymphoid and hematopoietic malignancies.

Authors:  Takao Takahashi; Narayan Shivapurkar; Jyotsna Reddy; Hisayuki Shigematsu; Kuniharu Miyajima; Makoto Suzuki; Shinichi Toyooka; Sabine Zöchbauer-Müller; Johannes Drach; Gunjan Parikh; Yingye Zheng; Ziding Feng; Steven H Kroft; Charles Timmons; Robert W McKenna; Adi F Gazdar
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531

Review 10.  Advances in biology of multiple myeloma: clinical applications.

Authors:  Teru Hideshima; P Leif Bergsagel; W Michael Kuehl; Kenneth C Anderson
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

View more
  12 in total

1.  Methylation of miR124a-1, miR124a-2, and miR124a-3 in Hodgkin lymphoma.

Authors:  M Ben Dhiab; S Ziadi; F Ksiaa; T Louhichi; R Ben Gacem; A Ben Zineb; K Amara; M Hachana; Mounir Trimeche
Journal:  Tumour Biol       Date:  2014-11-15

2.  Application of RUNX3 gene promoter methylation in the diagnosis of non-small cell lung cancer.

Authors:  Gui-Ping Yu; Yong Ji; Guo-Qiang Chen; Bin Huang; Kai Shen; Song Wu; Zhen-Ya Shen
Journal:  Oncol Lett       Date:  2011-10-19       Impact factor: 2.967

3.  Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma.

Authors:  Asma Beldi-Ferchiou; Nour Skouri; Cyrine Ben Ali; Ines Safra; Abderrahman Abdelkefi; Saloua Ladeb; Karima Mrad; Tarek Ben Othman; Mélika Ben Ahmed
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

Review 4.  Inside the human cancer tyrosine phosphatome.

Authors:  Sofi G Julien; Nadia Dubé; Serge Hardy; Michel L Tremblay
Journal:  Nat Rev Cancer       Date:  2011-01       Impact factor: 60.716

5.  Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma.

Authors:  Chor-Sang Chim; Raymond Liang; Tsz-Kin Fung; Chi-Lung Choi; Yok-Lam Kwong
Journal:  J Clin Pathol       Date:  2007-06       Impact factor: 3.411

6.  piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma.

Authors:  H Yan; Q-L Wu; C-Y Sun; L-S Ai; J Deng; L Zhang; L Chen; Z-B Chu; B Tang; K Wang; X-F Wu; J Xu; Y Hu
Journal:  Leukemia       Date:  2014-04-15       Impact factor: 11.528

7.  Epigenetic inactivation of the miR-124-1 in haematological malignancies.

Authors:  Kwan Yeung Wong; Chi Chiu So; Florence Loong; Lap Ping Chung; William Wai Lung Lam; Raymond Liang; George Kam Hop Li; Dong-Yan Jin; Chor Sang Chim
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

8.  Clinicopathological significance of p15 promoter hypermethylation in multiple myeloma: a meta-analysis.

Authors:  Bing Wei; Shuhua Yang; Bo Zhang; Yong Feng
Journal:  Onco Targets Ther       Date:  2016-07-01       Impact factor: 4.147

Review 9.  Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.

Authors:  Ana B Herrero; Elizabeta A Rojas; Irena Misiewicz-Krzeminska; Patryk Krzeminski; Norma C Gutiérrez
Journal:  Int J Mol Sci       Date:  2016-11-30       Impact factor: 5.923

10.  Clinicopathological significance of the p16 hypermethylation in multiple myeloma, a systematic review and meta-analysis.

Authors:  Huiqing Yu; Liejun Yang; Yunfeng Fu; Meng Gao; Ling Tian
Journal:  Oncotarget       Date:  2017-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.